Aarti Drugs Limited

Aarti Drugs Limited Share · INE767A01016 (XBOM) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Aarti Drugs Limited
No Price
Closing Price XBOM 30.04.2026: 374,05 INR
30.04.2026 09:59
Current Prices from Aarti Drugs Limited
ExchangeTickerCurrencyLast TradePriceDaily Change
XNSE: NSE
NSE
AARTIDRUGS.NS
INR
30.04.2026 09:59
377,00 INR
-
XBOM: MSE
MSE
AARTIDRUGS.BO
INR
30.04.2026 09:59
374,05 INR
-
Share Float & Liquidity
Free Float 38,76 %
Shares Float 35,37 M
Shares Outstanding 91,27 M
Company Profile for Aarti Drugs Limited Share
Aarti Drugs Limited, through its subsidiaries, engages in the manufacturing and marketing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company provides APls in various therapeutic areas, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemical products, such as benzene sulphonyl chloride, benzene sulphonic acid, benzene sulphonic acid methyl ester, sodium benzene sulfinate, para toluene sulphonyl chloride, para toluene sulphonic acid methyl ester, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, sodium para toluene sulfinate, para toluene sulphonyl hydrazide, di-phenyl sulphone, formamide, ammonium sulfate, and calcium fluoride, as well as benzene sulphonic acid sodium salt, benzyl nicotinate, methyl nicotinate, ethyl para toluene sulphonate, N-methyl methane sulfonamide, benzene sulphonamide, 2-phenoxy methane sulphanilide, para toluene sulfonamides, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, and N-methyl methane sulfonamides. In addition, the company's development products portfolio comprises Itraconazole and Fluconazole for antifungal applications; Dabigatran for use as an anticoagulant; Ticagrelor for cardiovascular diseases; Sitagliptin for use as an antidiabetics; and Alpha Lipoic Acid for application as an antioxidants. Further, it provides contract manufacturing services. Aarti Drugs Limited was incorporated in 1984 and is headquartered in Mumbai, India.

Company Data

Name Aarti Drugs Limited
Company Aarti Drugs Limited
Website https://www.aartidrugs.co.in
Primary Exchange XBOM MSE
ISIN INE767A01016
Asset Class Share
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Prakash Moreshwar Patil
Market Capitalization 34 Mrd.
Country India
Currency INR
Employees 1,1 T
Address Mahendra Industrial Estate, 400 022 Mumbai
IPO Date 2003-09-19

Stock Splits

Date Split
30.09.2020 4:1
24.03.2015 1:2

Ticker Symbols

Name Symbol
MSE AARTIDRUGS.BO
NSE AARTIDRUGS.NS
More Shares
Investors who hold Aarti Drugs Limited also have the following shares in their portfolio:
LB.HESS.THR.CARRARA06K/21
LB.HESS.THR.CARRARA06K/21 Bond
PIMCO RAE US Small Fund Class INSTL
PIMCO RAE US Small Fund Class INSTL Fund